Phase 1 N=18 A Study of Vorinostat in Patients With Solid Tumors (MK-0683-029)
Tumors
Primary: Number of Participants Who Experienced One or More Adverse Events — 4; 6; 3; 6 Participants
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 1 N=11 Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)
T-Cell Lymphoma Relapsed · Adult T-Cell Leukemia (ATL) · Peripheral T-Cell Lymphoma (PTCL)
Primary: Maximum Tolerated Dose (MTD) of Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) — 2 mcg/kg/dose
Phase 1 N=52 Dose, Safety, Tolerability and Immunogenicity of an Influenza H1 Stabilized Stem Ferritin Vaccine in Healthy Adults
Influenza Infection
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms Within 7 Days of Each H1ssF_3928 Product Administration — 5; 8; 11; 9 Participants
Phase 1 N=31 A Pilot Trial of Herpesvirus Treatment in Idiopathic Pulmonary Fibrosis (IPF)
Idiopathic Pulmonary Fibrosis
Primary: Proportion of Subjects Who Discontinue Study Drug Due to Adverse Events — 1; 0 Participants
Phase 1 N=51 Evaluating the Safety and Immunogenicity of AGS-v PLUS, a Universal Mosquito-Borne Disease and Mosquito Control Vaccine
Mosquito-Borne Infectious Diseases
Primary: Incidence of Severity of Treatment Emergent Adverse Events (AEs) by Grade — 7; 8; 10; 8 Participants
Phase 1 N=60 Evaluating the Safety and Immunogenicity of Env (A,B,C,A/E)/Gag (C) DNA and gp120 (A,B,C,A/E) Protein/GLA-SE HIV Vaccines, Given Individually or Co-administered, in Healthy, HIV-1-Uninfected Adults
HIV Infections
Primary: Number of Participants Reporting Local Reactogenicity Signs and Symptoms — 2; 5; 5; 3 Participants
Phase 1 N=27 Eribulin Mesylate and Everolimus in Treating Patients With Triple-Negative Metastatic Breast Cancer
Estrogen Receptor Negative · HER2/Neu Negative · Progesterone Receptor-negative
Primary: Number of Participants Experiencing a Dose Limiting Toxicity (DLT) (Phase I) and the Recommended Phase IB Dose (RP2D) — 4; 4; 2 Participants
Phase 1 N=54 General Anesthesia Emergence Induced by Methylphenidate
Delayed Emergence From Anesthesia
Primary: Emergence Time — 9; 9 minutes
Phase 1 N=174 Study Of OX40 Agonist PF-04518600 Alone And In Combination With 4-1BB Agonist PF-05082566
Neoplasms
Primary: Number of Participants With Dose Limiting Toxicities (DLTs) in Part A1 — 0; 0; 0; 0 Participants
Phase 1 N=80 COVID-19 Convalescent Plasma for the Treatment of Hospitalized Patients With Pneumonia Caused by SARS-CoV-2.
COVID-19
Primary: Participants With Serious Adverse Events. — 12; 15 Participants
Phase 1 N=20 A Study to Evaluate the Effects of Rifampin on Pharmacokinetics (PK) of Pevonedistat in Participants With Advanced Solid Tumors
Advanced Solid Neoplasm
Primary: Part A: Ratio of Maximum Observed Plasma Concentration (Cmax) for Pevonedistat Without Rifampin (Day 1) and With Rifampin (Day 10) — 0.962 ratio
Phase 1 N=20 Nivolumab and Tumor Infiltrating Lymphocytes (TIL) in Advanced Non-Small Cell Lung Cancer
Non-Small Cell Lung Cancer · Metastatic Non-small Cell Lung Cancer · Squamous Cell Carcinoma
Primary: Rate of Dose Limiting Toxicity (DLT) — 17 % participants w severe toxicity
Phase 1 N=42 A Study to Determine the Bioequivalence of Oraxol in Cancer Patients Treated With Intravenous Paclitaxel
Solid Tumor
Primary: Area Under the Concentration-Time Curve Zero Time Extrapolated to Infinite Time (AUC0-∞) — 5033.5; 5595.9 ng*h/mL
Phase 1 N=42 Characterization of Skin Immunity to Aedes Aegypti Saliva in Dengue-endemic Participants in Cambodia
Vector Borne Diseases
Primary: Measurement of Change in Early and Late Innate Immune Responses Using Gene Expression and Flow Cytometry in Participants' Skin — 50; 5 % of total dendritic cells
Phase 1 N=3 A Phase I Trial of AZD3965 in Patients With Advanced Cancer
Adult Solid Tumor · Diffuse Large B Cell Lymphoma · Burkitt Lymphoma
Primary: MTD of AZD3965 — 10 mg (twice daily)